SLU-PP-332 (research reagent)

SLU-PP-332

SLU-PP-332 is a research compound described in the scientific literature as an agonist of the ERR receptors (estrogen-related receptors). The ERR receptors (ERRα, ERRβ, ERRγ) belong to the orphan nuclear receptor superfamily and are the subject of intensive research into energy metabolism, mitochondrial biogenesis and skeletal-muscle function. SLU-PP-332 appears in peer-reviewed literature as a pharmacological tool compound used to probe the activity of this receptor family in experimental models.

The substance is usually supplied as a research-grade powder or solution. Because it is a niche research reagent, several of its physicochemical parameters do not have unambiguously confirmed, publicly verified values — such fields are marked below so that uncertain analytical data are not presented as certain.

Physicochemical data

Characteristics and research application

SLU-PP-332 is used in basic research as an agonist of the ERR receptors — a class of nuclear receptors that regulate the expression of genes involved in oxidative metabolism, mitochondrial function and cellular energy balance. In the scientific literature this compound is indicated as a research tool for analysing ERR-dependent signalling pathways in in vitro and preclinical in vivo models, conducted exclusively under laboratory conditions.

The product is offered as a compound for advanced laboratory research, intended for reference work, validation of analytical methods and experiments carried out by qualified personnel. Because it is a relatively new research reagent with a limited set of widely available, confirmed physicochemical data, independent verification of the identity and purity of the material by instrumental methods (NMR, LC-MS, HPLC) on the basis of the Certificate of Analysis supplied with the given batch is strongly recommended.

The reagent is not intended for diagnostic, therapeutic or consumer use. Responsibility for the lawful and safe use of the substance rests with the purchaser acting as a research entity.